Abstracts tagged "Anti-TNF Drugs"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Daniel Aletaha¹, Dr. Carmen Bremer², Jack Milligan³, Zichun Cao⁴, Rachael Meadows³ and Xenofon Baraliakos⁵, ¹Medical University Vienna, Wien, Austria, ²Sandoz International GmbH, Holzkirchen, Germany, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Sandoz Incorporated, Princeton, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…
Abstract Number: 0560 • ACR Convergence 2025
Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
Ayantika Talukdar¹, Phuong Nguyen², Neke Ibeke³, Rohan Machhar¹, Mansi Aparnathi¹, Archita Srinath², Akihiro Nakamura⁴, Robert Inman³, Igor Jurisica⁵, Proton Rahman⁶, Nigil Haroon⁷ and Sareh Keshavarazi¹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Queen's University, Kingston, ON, Canada, ⁵University Health Network, Toronto, Canada, ⁶Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is a type of chronic inflammatory arthritis affecting the spine and peripheral joints. Although tumor necrosis factor inhibitors (TNFi) substantially improve…
Abstract Number: 2268 • ACR Convergence 2025
Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Clementina López Medina¹, Rafaela Ortega-Castro², Francisco Jose Cepas³, Montserrat Robustillo-Villarino⁴, Andres Zuniga-Vera⁴, Ana Martinez-Feito⁵, Ester Costa-Moya⁶, Delia Taverner-Torrent⁶, Luis Sainz Comas⁷, Cesar Diaz-Torne⁷, Virginia Ruiz-Esquide⁸, Cynthia Rojas⁹, Lourdes Martin-de la Sierra Lopez¹⁰, Laura Jimenez-Rodriguez¹⁰, David Velasco-Sanchez¹⁰, Regina Fará Garcia¹¹, Antonio Juan-Mas¹², Marina soledad Moreno Garcia¹³, Ana Valeria Acosta Alfaro¹⁴, Santiago Muñoz¹⁵, Maria Martín López¹⁶, Raquel Zas¹⁷, FRANCISCO JAVIER GODOY NAVARRETE¹⁸, Isabel Anon Onate¹⁹, Fernando Ortiz-Márquez²⁰, Natalia Mena Vázquez²¹, Paula Estrada-Alarcón²², Jerusalén Calvo²³, Alejandro Escudero Contreras²³ and Chamaida Plasencia-Rodríguez²⁴, ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁵Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁶Hospital Sant Joan Reus, Reus, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹Hospital Clinic, Barcelona, Spain, ¹⁰Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹¹Hospital Son Llàtzer, Palma, Spain, ¹²Son Llazter University Hospital, Madrid, Spain, ¹³Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁴Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁶Hospital ¹² de Octubre, Madrid, Spain, ¹⁷Hospital Universitario Doce de Octubre, Madrid, Spain, ¹⁸Jaen University Hospital, Spain, Jaen, Spain, ¹⁹Hospital Universitario de Jaén, Jaén, Spain, ²⁰Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²¹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ²⁴Hospital Universitario La Paz, MADRID, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody that contributes to the development of rheumatoid arthritis (RA) and is associated with greater disease severity. Seroconversion of…
Abstract Number: 0855 • ACR Convergence 2025
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Jane Salmon¹, Mimi Kim², Marta Guerra¹, Joseph Worden³, Carl Laskin⁴, Maria DeSancho⁵, Inna Landres⁵, Jason S. Knight⁶, Haley Slosberg¹, Margaret Minett¹ and Ware Branch⁷, ¹Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Utah School of Medicine, Salt Lake City, ⁴University of Toronto, Toronto, ON, Canada, ⁵Weill Cornell Medicine, New York, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Utah Health Sciences Center, Salt Lake City, UT
Background/Purpose: The IMPACT trial (NCT03152058) showed that certolizumab appears effective in preventing placenta-mediated adverse pregnancy outcome (APO) in high-risk antiphospholipid syndrome (APS) patients. We have…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 0537 • ACR Convergence 2025
HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
Kent LE¹, Hervé LOCRELLE¹, Myriam NORMAND¹, Irina COMAN¹, Louis DELENTE¹, Tiphany NEEL¹, Adamah AMOUZOUGAN¹, Thierry THOMAS¹ and Hubert Marotte², ¹Service Rhumatologie Hôpital Nord, Saint-Etienne, France, ²INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France
Background/Purpose: To assess the prevalence, risk factors and treatment-related outcomes of uveitis in patients with spondyloarthritis (SpA), using data from a 15-year real-life cohort.Methods: We…
Abstract Number: 2042 • ACR Convergence 2025
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Natalia Lopez Juanes¹, Carlota Ureta¹, Marta Novella-Navarro¹, Irene Monjo Henry¹, Diana Peiteado¹, Alejandro Villalba¹, Laura Nuño², Victoria Navarro-Compan³, María Sanz¹, Mª ángeles Gonzalez¹, Cristina Suarez⁴, Agustin Remesal¹, Rosa Alcobendas⁵, Clara udaondo¹, Elena Sendagorta⁵, Alejandro Balsa¹, Eugenio de Miguel¹ and Chamaida Plasencia-Rodríguez¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁵La Paz University Hospital, Madrid, Spain
Background/Purpose: The combination of biological (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has emerged as a promising approach to improve clinical outcomes in immune-mediated inflammatory diseases…
Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…
Abstract Number: 1677 • ACR Convergence 2025
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Task Toyoda¹, Kerem Abacar¹, Farag Shuweihdi², Megan Sheridan³, Jacqueline Nam³, Ai Lyn Tan⁴, Lesley-Anne Bissell³, Paul Emery⁵ and Kulveer Mankia⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ²Dental Translational and Clinical Research Unit, School of Medicine, University of Leeds, Leeds, England, United Kingdom, ³Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ⁵University of Leeds, Leeds, England, United Kingdom
Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 2644 • ACR Convergence 2025
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
Kathryne Marks¹, Alice Horisberger², Ifeoluwakiisi Adejoorin¹, Leah Santacroce¹, Mehreen Elahee³, Joan Bathon⁴, Kevin Wei⁵, Daniel Solomon⁶ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³Brigham and Women's Hospital, Wexford, PA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: TNF inhibitors (TNFi) are the most common biologic DMARD used to treat RA; however, no robust biomarkers have been established to predict likelihood of…
Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Alexia Zagouras¹, Sammy Pickell¹, Yuhan Liu¹, Ronald Witteles¹ and Matthew Charles Baker², ¹Stanford University, Stanford, CA, ²Stanford University, Menlo Park, CA
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
Abstract Number: 0402 • ACR Convergence 2025
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Dawn Gist¹, Andrea Ramirez¹, Jamie Lai², Duc Nguyen¹ and Kexin Guo¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, The Woodlands, TX
Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…
Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Rachael Stovall¹, Cinthia Blat², Eric Roberts³, Jean Liew⁴, Katherine Wysham⁵, Namrata Singh¹, Janna Friedly¹, Lianne S. Gensler⁶, gabriela Schmajuk⁷ and Jinoos Yazdany⁸, ¹University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, SF, CA, ⁴Boston University School of Medicine, Boston, MA, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁸UCSF, San Francisco, CA
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…

1
2
3
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].